Make personalized cancer vaccines possible for every dog.

Personalized mRNA cancer vaccines for dogs are an emerging modality. The same neoantigen-targeting approach now in late-stage human trials, including Moderna and Merck's mRNA-4157 in melanoma and BioNTech's autogene cevumeran in pancreatic cancer, can be adapted for canine biology. RosieVaccine is developing this approach. No RosieVaccine product is currently licensed or commercially available, and any administration to a dog would occur only after the required USDA-APHIS CVB and state authorizations, under a research protocol, through the dog's own veterinary oncologist.

No RosieVaccine product is currently licensed or for sale, so there is no rate to publish. The line items in a future authorized workflow would typically include tumor and germline sequencing, our design work, and mRNA synthesis through our CDMO partner.

Tumours with a reasonable somatic mutation burden, meaning the cancer carries enough unique mutations to give the immune system clear targets, work best. Our primary focus has been mast cell tumours, melanoma, osteosarcoma and hemangiosarcoma. We discuss case fit individually with the veterinary oncologist before accepting a pilot.

This is the most common first question, and the single most important thing is to act before the sample is discarded. The gold standard is fresh-frozen tissue: a piece of the tumor snap-frozen in liquid nitrogen within about 30 minutes of removal, cut into small (3–5 mm) pieces, split across several vials, and never allowed to thaw. In practice, most tumors are already fixed in formalin and embedded in paraffin (an FFPE block) by the pathology lab, and that is workable too. FFPE is used routinely for tumor DNA sequencing, though it yields lower-quality DNA than fresh-frozen. We also need a matched normal sample, a simple blood draw in an EDTA tube, to tell your dog's inherited DNA apart from the cancer's mutations. If surgery has already happened, the time-sensitive step is to ask your vet to have the histopathology lab place a hold on whatever tumor material remains (block and/or slides), because labs routinely discard specimens after a set window. Always let your surgeon and oncologist lead the clinical side. Read our full guide to preserving a tumor sample →

Chemotherapy attacks the tumor directly, often with significant side effects on healthy cells. A personalized cancer vaccine instead trains the dog's own immune system to recognize the specific mutations that distinguish the tumor from healthy tissue. The two approaches can be complementary, since many human protocols use both, and a personalized vaccine is typically offered adjuvant to standard of care, not as a replacement for it.

Your veterinary oncologist, under their existing clinical judgment and ethics framework. RosieVaccine is a bioinformatics design service. We do not manufacture vaccines, treat patients, or practice veterinary medicine. The synthesized vaccine ships back to your clinic in a cold-chain shipment with a printed dosing schedule; administration happens entirely under your oncologist's care.

Veterinary biologics in the United States are regulated by the USDA, not the FDA. No RosieVaccine product is currently licensed or commercially available, and we do not currently hold a USDA Autologous Prescription Product (APP) license. Any administration to a client-owned dog would occur only after the required USDA-APHIS CVB and state authorizations, under a research protocol and the oversight of the dog's own licensed veterinary oncologist.

Through your veterinary oncologist, not directly. If your oncologist would like to explore whether a personalized mRNA approach could fit your dog, they can register their interest through the form on this page and we'll talk with them. Registering interest is not access to treatment: no product is licensed or available today, and any future administration would occur only after the required USDA-APHIS CVB and state authorizations, under a research protocol.